Literature DB >> 12369004

The influence of preoperative chemotherapy and surgical technique in the treatment of hepatoblastoma--a report from the German Cooperative Liver Tumour Studies HB 89 and HB 94.

J Fuchs1, J Rydzynski, H Hecker, H Mildenberger, D Bürger, D Harms, D V Schweinitz.   

Abstract

UNLABELLED: Despite the success of chemotherapy in the treatment of hepatoblastoma (HB), the complete surgical resection of the primary liver tumour and metastases is the most important factor for survival.
METHODS: From 1989 to 1998, 141 children with HB were treated in the German Cooperative Paediatric Liver Tumour Study HB 89 and HB 94. The study determines the results of surgical strategy, which adapts the procedure at the initial operation to the tumour extension in the liver and the occurrence of metastases.
RESULTS: The median follow-up of the survivors was 72 months (range 24 - 132 months). 98/141 (78 %) patients were alive and 31/141 (22 %) died. 12/141 (8.5 %) children had no surgical treatment. A complete resection of the primary tumour was achieved in 107/129 (83 %) cases. Forty-eight children were primary resected and eighty-one children were operated on after initial chemotherapy. In 36 cases, an atypical tumour resection, in 90 cases an anatomical liver resection, was performed. Three children were transplanted. There was no perioperative death. 14/48 (30 %) children with primary tumour resection had microscopical or macroscopical residual tumour in the liver. Despite the larger number of advanced HB in the primary chemotherapy group, an incomplete tumour resection was performed in only 15/78 (19 %) cases after liver resection (p < 0.044). 14/36 (38 %) cases with atypical tumour resection and only 16/90 (18 %) cases with anatomical liver resection had residual tumours in the liver (p < 0.019). These results underline the necessity for preoperative chemotherapy in all HB, which was accepted in the following study HB 99. Atypical tumour resection should be avoided because of the higher rate of incomplete tumour resections and local relapse compared to the group with anatomical tumour resection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12369004     DOI: 10.1055/s-2002-34484

Source DB:  PubMed          Journal:  Eur J Pediatr Surg        ISSN: 0939-7248            Impact factor:   2.191


  9 in total

Review 1.  Surgical treatment of hepatoblastoma in children.

Authors:  Piotr Czauderna; Jean-Bernard Otte; Derek J Roebuck; Dietrich von Schweinitz; Jack Plaschkes
Journal:  Pediatr Radiol       Date:  2006-01-11

2.  Teratoid Hepatoblastoma with Multi-Lineage Differentiation: An Uncommon Histological Variant and Review of Literature.

Authors:  Mayur Parkhi; Suvradeep Mitra; Debajyoti Chatterjee; Nitin J Peters
Journal:  J Clin Exp Hepatol       Date:  2022-04-10

3.  International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Authors:  Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle
Journal:  Ecancermedicalscience       Date:  2022-02-17

4.  Comparison of Cisplatin Monotherapy and PLADO in the Management in Children with Standard-Risk Hepatoblastoma in a Resource-Challenged Nation.

Authors:  Sandeep Agarwala; Vishesh Jain; Anjan Dhua; Madur Srinivas; Prabudh Goel; Sameer Bakhshi; Venkateswaran K Iyer; Rajni Yadav; Manisha Jana; Priyanka Naranje; Veereshwar Bhatnagar
Journal:  J Indian Assoc Pediatr Surg       Date:  2022-05-12

5.  Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study.

Authors:  Howard M Katzenstein; Marcio H Malogolowkin; Mark D Krailo; Jin Piao; Alexander J Towbin; M Beth McCarville; Gregory M Tiao; Stephen P Dunn; Max R Langham; Eugene D McGahren; Milton J Finegold; Sarangarajan Ranganathan; Christopher B Weldon; Patrick A Thompson; Angela D Trobaugh-Lotrario; Allison F O'Neill; Wayne L Furman; Nadia Chung; Jessica Randazzo; Carlos Rodriguez-Galindo; Rebecka L Meyers
Journal:  Cancer       Date:  2021-11-11       Impact factor: 6.921

6.  Hepatoblastoma: a single institutional experience of 18 cases.

Authors:  Parul J Shukla; Savio G Barreto; Sajid S Qureshi; Rohini Hawaldar; Shailesh V Shrikhande; Mukta R Ramadwar; Shripad Banavali
Journal:  Pediatr Surg Int       Date:  2008-05-06       Impact factor: 1.827

Review 7.  Complete resection of hepatoblastoma originating in the caudate lobe: case report and literature review.

Authors:  Hiroyuki Koga; Yoichi Ishizaki; Junya Fujimura; Tadaharu Okazaki; Naho Fujiwara; Geoffrey J Lane; Toshiaki Shimizu; Atsuyuki Yamataka; Seiji Kawasaki
Journal:  Pediatr Surg Int       Date:  2009-11       Impact factor: 1.827

8.  Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children's Oncology Group.

Authors:  Rebecka L Meyers; Jon R Rowland; Mark Krailo; Zhengjia Chen; Howard M Katzenstein; Marcio H Malogolowkin
Journal:  Pediatr Blood Cancer       Date:  2009-12       Impact factor: 3.167

9.  Surgical Resection for Hepatoblastoma-Updated Survival Outcomes.

Authors:  Bhanu Jayanand Sunil; Ravisankar Palaniappan; Balasubramanian Venkitaraman; Rama Ranganathan
Journal:  J Gastrointest Cancer       Date:  2018-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.